



BIOSENSORS  
INTERNATIONAL

**NEWS RELEASE**

**BIOSENSORS ANNOUNCES AGREEMENT TO ACQUIRE FIFTY  
PERCENT OF JW MEDICAL SYSTEMS LIMITED**

**Singapore, 10 Aug 2007** – Biosensors International Group, Ltd. (Bloomberg: BIG SP, “Company” or “Biosensors”), today announced it has entered into a conditional sale and purchase agreement to acquire fifty percent of JW Medical Systems Ltd (“JWMS”) from JW Medical Ltd, a company incorporated in the British Virgin Islands, for cash consideration of US\$10.0 million and 129 million new shares of Biosensors’ ordinary stock. The acquisition is subject to customary closing conditions and completion of due diligence, and is expected to close by 25 September 2007. JWMS is a privately-owned drug-eluting stent manufacturer based in Weihai, in the Province of Shandong, China. The remaining 50 percent of JWMS is owned by Shandong Weigao Group Medical Polymer Co. Ltd (“Weigao”).

The acquisition of 50 percent of JWMS extends the strategic relationship between Biosensors and Weigao established in 2003 when the companies formed a successful joint-venture to manufacture critical care products in China.

Commenting on this acquisition, Mr. Lu Yoh Chie, Chairman and Chief Executive Officer said, “This acquisition strengthens the operating capabilities of Biosensors and we believe that our relationship with Weigao and JWMS will accelerate the execution of our strategy to penetrate the fast-growing Chinese market and eventually introducing Biosensors’ innovative technologies in China.”

At the close of its fiscal year, ending 31 December 2006, less than a year after commercialization of its Excel drug-eluting stent, JWMS reported sales of approximately US\$20.0 million and net income of approximately US\$8.5 million, a net profit margin of approximately 41 percent.

While recent trends in many major markets indicate that the usage of drug-eluting stents is declining as more bare-metal stents are being used, the usage of drug-eluting stents in the Asia Pacific market outside of Japan remains in excess of 90 percent. According to market data, demand for drug-eluting stents in key markets within Asia Pacific, outside of Japan, grew from US\$258 million in the first six months of calendar 2006 to US\$361 million in the first half of 2007. A majority of this growth is attributable to China. For the first six months of 2007, the drug-eluting stent market in China more than doubled to US\$184.0 million compared to US\$89.0 million for the first six months of 2006 and this rapid growth rate of the drug-eluting stent market in China is expected to continue.

Mr Lu Yoh Chie Chairman and CEO added, “Excel has been very well-received since its approval in early 2006. It is now the third largest drug-eluting stent player in China in terms of market share. JWMS has conducted several large-scale clinical trials in China involving over 2,000 patients and has reported very strong clinical results from these trials, including the presentation of highly positive clinical results of the Excel drug-eluting stent at the Transcatheter Coronary Therapeutics Conference (“TCT 2006”) held in Washington D.C., United States in October 2006. The quality of the Excel stent, JWMS’s strong Chinese distribution network and the rapidly growing market in China position JWMS for continued growth.”

Mr. Lu concluded, “Our investment in JWMS provides Biosensors an opportunity to participate in the China market immediately. Biosensors also plans to utilize JWMS’s extensive distribution network and manufacturing efficiencies, to accelerate the commercialization of our own new drug-eluting stent technologies such as BioMatrix™ when it is approved in the China market. Additionally, combining our core drug-eluting stent technologies with JWMS’s extensive distribution network will enable Biosensors to become a formidable player in China. We believe that this investment is an important element in our plans to establish a global presence in the drug-eluting stent market while we will remain focused on our efforts to obtain regulatory approvals in Europe and the United States.”

The Company has released an announcement of this acquisition on SGXNET and the same announcements also available on the Company’s corporate website at [www.biosensors.com](http://www.biosensors.com) under Investor Relations section.

## End of Release ##

**Media & Investor Relations**

**Singapore**

Mr. Loh Chee Mun

Senior Vice President

Tel: (65) 62135708

Email: [cm.loh@biosensors.com](mailto:cm.loh@biosensors.com)

## **United States**

### ***Allen&Caron Inc***

Mr. Matt Clawson

Executive Vice President, Investor Relations

Tel: (1) 949 474 4300

Email: [matt@allencaron.com](mailto:matt@allencaron.com)

## **About Biosensors International Group, Ltd**

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary anti-restenosis drug. It is pursuing three separate drug-eluting stent programs, *BioMatrix*<sup>®</sup>, *Axxion*<sup>™</sup>, and *BioMatrix*<sup>®</sup> Freedom<sup>™</sup>, a polymer-free drug-eluting stent, and has licensed aspects of its drug-eluting stent technology to four companies.

## **About Shandong Weigao Group Medical Polymer Company Limited**

Weigao is a leading player in research, development, production and sale of single-use medical devices. It has a wide product range in a) infusion/transfusion sets; b) syringes; c) blood bags; and d) medical needles. It has also successfully entered the high value added market segments with products in orthopaedic, blood purification and drug-coated stent. Weigao has a nationwide sales network and an extensive customer base of over 5,400 healthcare organizations including over 2,700 hospitals and 400 blood stations. The Company is actively exploring opportunities in international markets and its products are exported to countries, including U.S. and European countries.

## **Forward Looking Statements**

*Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.*